The Center for Treatment Resistant Depression at CPC
Major Depressive Disorder (MDD) is a condition that affects over 16 million Americans on a daily basis. Traditional treatments such as medication and evidence based-psychotherapy provide relief for some individuals suffering from depression.
However, there remain a significant portion of individuals, approximately 6.4 million Americans, who do not respond to these treatment modalities. For those individuals who continue to experience depression, despite the aforementioned treatments, there are more options available.
In 2022, Comprehensive Psychiatric Care (CPC) launched its Center for Treatment Resistant Depression. The purpose of this specialty center is to offer a wide range of treatments for individuals suffering from depression. CPC has an established history of providing care for depressed individuals, dating back over 40 years. In 2008, we were the first practice in CT to offer Transcranial Magnetic Stimulation (TMS) services for Treatment Resistant Depression (TRD). Since that time we have successfully completed over 4800 treatments with our Neurostar TMS system. Additionally, beginning in 2001, CPC began conducting clinical trials for various mental health diagnosis including MDD and TRD.
Services Now Offered at CPC’s Center for Treatment Resistant Depression
- Transcranial Magnetic Stimulation (TMS): An FDA approved non-invasive procedure using magnetic pulses to treat TRD. Learn More Here >
- Spravato es-Ketamine: An FDA approved self-administered nasal spray, using es-Ketamine, in combination with another anti-depressant to treat TRD. Learn More Here >
- Clinical Research: MDD trials enrolling with novel compounds, not available outside of clinical trials. No insurance is needed, volunteers compensated.
For more information or to determine if you are a good candidate, click here.
- Medication Management: These services are offered to patients on an outpatient basis with a focus on TRD treatment as indicated.
- Evidence Based Therapy: Licensed, experienced clinicians with focus on reducing the burdens and symptoms of TRD.